Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Immunotherapy of multiple sclerosis: Where are we? Where should we go?

Nature Immunology volume 2, pages 785–788 (2001)Cite this article

Differences in multiple sclerosis patient's disease and their responses to standard drugs indicate that today's therapies need to be more individualized. It is proposed that gene expression profiling in conjunction with magnetic resonance imaging be used to optimize future treatment approaches.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic depiction of the pathogenetic steps that lead to tissue damage in MS.
Figure 2: Longitudinal course of the fluctuations of contrast-enhancing MRI lesions in a patient who responded to IFN-β treatment.
Figure 3: Identification of responders and nonresponders to immunomodulatory treatment with IFN-β.

References

  1. Bielekova, B. & Martin, R. Curr. Treat. Options Neurol. 1, 201–219 (1999).

    Article  CAS  PubMed  Google Scholar 

  2. McFarlin, D. E. & McFarland, H. F. New Engl. J. Med. 307, 1183–1188 (1982).

    Article  CAS  PubMed  Google Scholar 

  3. McFarlin, D. E. & McFarland, H. F. New Engl. J. Med. 307, 1246–1251 (1982).

    Article  CAS  PubMed  Google Scholar 

  4. Martin, R., McFarland, H. F. & McFarlin, D. E. Annu. Rev. Immunol. 10, 153–187 (1992).

    Article  CAS  PubMed  Google Scholar 

  5. Prineas, J. W. in Handbook of Clinical Neurology, Demyelinating Diseases (eds Vinken, P. J., Bruyn, G. W., Klawans, H. L. & Koetsier, J. C.) Vol. 3 Ch. 47 213–257 (Amsterdam/New York, Elsevier Science, 1985).

    Google Scholar 

  6. Zamvil, S. S. & Steinman, L. Annu. Rev. Immunol. 8, 579–621 (1990).

    Article  CAS  PubMed  Google Scholar 

  7. Ota, K. et al. Nature 346, 183–187 (1990).

    Article  CAS  PubMed  Google Scholar 

  8. Lucchinetti, C. et al. Ann. Neurol. 47, 707–717 (2000).

    Article  CAS  PubMed  Google Scholar 

  9. McFarland, H. F. et al. Ann. Neurol. 32, 758–766 (1992).

    Article  CAS  PubMed  Google Scholar 

  10. Becker, K. G. et al. Proc. Natl Acad. Sci. USA 95, 9979–9984 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 45, 1277–1285 (1995).

  12. Johnson, K. P. et al. Neurology 45, 1268–1276 (1995).

    Article  CAS  PubMed  Google Scholar 

  13. Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I. & Hafler, D. A. J. Clin. Invest. 105, 967–976 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wandinger, K. P. et al. Ann. Neurol. 10 (in the press, 2001).

  15. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 53, 457–465 (1999).

  16. Moalem, G. et al. Nature Med. 5, 49–55 (1999).

    Article  CAS  PubMed  Google Scholar 

  17. Owens, T., Wekerle, H. & Antel, J. Nature Med. 7, 161–166 (2001).

    Article  CAS  PubMed  Google Scholar 

  18. Hohlfeld, R. Brain 120, 865–916 (1997).

    Article  PubMed  Google Scholar 

  19. Kennedy, M. K., Tan, L.-J., Dal Canto, M. C. & Miller, S. D. J. Immunol. 145, 117–126 (1990).

    CAS  PubMed  Google Scholar 

  20. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. & Kuchroo, V. K. Immunity 3, 397–405 (1995).

    Article  CAS  PubMed  Google Scholar 

  21. Bielekova, B. et al. Nature Med. 6, 1167–1175 (2000).

    Article  CAS  PubMed  Google Scholar 

  22. Kappos, L. et al. Nature Med. 6, 1176–1182 (2000).

    Article  CAS  PubMed  Google Scholar 

  23. Jacobs, L. D. et al. New Engl. J. Med. 343, 898–904 (2000).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroimmunology Branch, NINDS, National Institutes of Health, Building 10, Room 5B-16, 10 Center DR MSC 1400, Bethesda, 20892-1400, MD, USA

    Roland Martin & Henry F. McFarland

  2. Clinical Development CNS, Schering AG, Berlin, 13342, Germany

    Claus-Steffen Stürzebecher

Authors
  1. Roland Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claus-Steffen Stürzebecher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henry F. McFarland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, R., Stürzebecher, CS. & McFarland, H. Immunotherapy of multiple sclerosis: Where are we? Where should we go?. Nat Immunol 2, 785–788 (2001). https://doi.org/10.1038/ni0901-785

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ni0901-785

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing